Dedicated to enabling surgical administration of novel cell and gene therapies.
EpiHeart and the University of Edinburgh's Centre for Cardiovascular Science have entered into a collaboration to develop advanced therapies for the treatment of heart failure. The multi-year collaboration is supported by Medical Research Scotland.
Advanced gene therapies offer the ultimate potential to repair damaged hearts by targeting cell signalling and protein production. The Centre for Cardiovascular Science, part of the University of Edinburgh, is a world leader in cardiovascular gene therapy research. EpiHeart enables Cardiac Micrograft Therapy™, an autologous cell therapy delivered during heart surgery.
"The combination of gene therapy and Cardiac Micrograft Therapy™ is extremely exciting for two reasons. Firstly, there is clearly potential for novel therapeutic approaches to be explored. Secondly, the epicardial treatment approach enables unique features, including precise dosing, local administration and reduced systemic exposure," says Kai Kronström, CEO of EpiHeart.
"I believe this collaboration with EpiHeart not only supports basic science, but also has the potential to reduce the burden of transitioning from laboratory into clinical research," says Professor Andrew Baker, Head of the Centre for Cardiovascular Science.
Kai Kronström, co-founder and CEO of EpiHeart, says: "We are honoured to be working with the team led by Professor Baker. The support from Medical Research Scotland has been invaluable. We look forward to a fruitful collaboration".
Further information may be requested:
Kai Kronström, EpiHeart CEO, email@example.com
EpiHeart is a University spin-off company leveraging over 10 years of dedicated research conducted on three continents. We are based in Helsinki, Finland, where we continue collaboration with University of Helsinki, Helsinki University Hospital "HUS" and Aalto University.
EpiHeart is dedicated to enable new treatments that improve long term survival and quality of life of cardiac patients. Our initial focus is in Cardiac Micrograft Therapy™. The pre-clinical and clinical results indicate positive effects on ventricular wall structure and scar size - critical factors contributing to heart failure.
EpiHeart is conducting clinical studies. We are open for collaboration with EU and US based cardiac surgery units and distributors. Our collaboration covers also research and commercial partnerships related to advanced cell and gene therapies that could be administered surgically.
Company profile video (English, Finnish and German subtitles available)